Zydus Cadila Takes Teva To Virginia Court Asserting Rights Over Risperidone APIs
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - As the battle for six-month exclusivity on blockbuster drugs going off-patent intensifies in the U.S., generic companies are opening up a new war front - the quest for patent rights over bulk drugs or active ingredients that go into manufacturing multi-billion dollar drugs
You may also be interested in...
U.S. Court Dismisses Teva’s Patent Infringement Plea Against Dr Reddy’s Carvedilol; Dr Reddy’s May Launch Drug Soon
MUMBAI - Dr Reddy's Labs may be able to sell generic versions of GlaxoSmithKline's hypertension drug Coreg (carvedilol) in the U.S. after it settled a case against Israeli drug maker Teva for four patents of the drug
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).